International Journal of Molecular Medical Science, 2024, Vol.14, No.4, 216-226 http://medscipublisher.com/index.php/ijmms 226 Rosenblat J., Lee Y., and McIntyre R., 2017, Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? a systematic review of clinical trials and cost-effectiveness studies, The Journal of Clinical Psychiatry, 78(6): 720-729. https://doi.org/10.4088/JCP.15r10583 Sadeeqa S., 2018, Depression: a case study, Alzheimer's Research and Therapy Open Access, 1(1): 19. https://doi.org/10.4324/9780203380383-19 Sekaran K., and Shanmugam S., 2021, Predicting drug responsiveness by citalopram induced pathway regulations and biomarker discovery in lymphoblastoid cell lines from depression affected individuals, 2021 International Conference on Decision Aid Sciences and Application (DASA), (2021): 267-271. https://doi.org/10.1109/DASA53625.2021.9682274 Shadrina M., Bondarenko E., and Slominsky P., 2018, Genetics factors in major depression disease, Frontiers in Psychiatry, 9: 334. https://doi.org/10.3389/fpsyt.2018.00334 Singh P., Srivastava A., Guin D., Thakran S., Yadav J., Chandna P., Sood M., Chadda R., and Kukreti R., 2023, Genetic landscape of major depressive disorder: assessment of potential diagnostic and antidepressant response markers, International Journal of Neuropsychopharmacology, 26: 692-738. https://doi.org/10.1093/ijnp/pyad001 Tanner J., Davies P., Voudouris N., Shahmirian A., Herbert D., Braganza N., Gugila A., DeChairo B., and Kennedy J., 2018, Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists, Journal of Psychiatric Research, 104: 157-162. https://doi.org/10.1016/j.jpsychires.2018.07.012 Thase M., Parikh S., Rothschild A., Dunlop B., Debattista C., Conway C., Forester B., Mondimore F., Shelton R., Macaluso M., Li J., Brown K., Jablonski M., and Greden J., 2019, Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial, The Journal of Clinical Psychiatry, 80: 6. https://doi.org/10.4088/JCP.19m12910 Tuson M., Pérez V., Salavert A., Mazo J., and Menchón J., 2017, Pharmacogenomic information in the treatment of major depression: results from a randomized clinical trial, European Neuropsychopharmacology, 27: S364-S365. https://doi.org/10.1016/j.euroneuro.2016.09.388 Wray N., Ripke S., Mattheisen M., Trzaskowski M., Byrne E., Abdellaoui A., Adams M., Agerbo E., Air T., Andlauer T., Bacanu S., Bækvad-Hansen M., Beekman A., Bigdeli T., Binder E., Blackwood D., Bryois J., Buttenschøn H., Bybjerg-Grauholm J., Cai N., Castelao E., Christensen J., Clarke T., Coleman J., Colodro-Conde L., Couvy-Duchesne B., Craddock N., Crawford G., Crowley C., Dashti H., Davies G., Deary I., Degenhardt F., Derks E., Direk N., Dolan C., Dunn E., Eley T., Eriksson N., Escott-Price V., Kiadeh F., Finucane H., Forstner A., Frank J., Gaspar H., Gill M., Giusti-Rodríguez P., Goes F., Gordon S., Grove J., Hall L., Hannon E., Hansen C., Hansen T., Herms S., Hickie I., Hoffmann P., Homuth G., Horn C., Hottenga J., Hougaard D., Hu M., Hyde C., Ising M., Jansen R., Jin F., Jorgenson E., Knowles J., Kohane I., Kraft J., Kretzschmar W., Krogh J., Kutalik Z., Lane J., Li Y., Li Y., Lind P., Liu X., Lu L., Macintyre D., MacKinnon D., Maier R., Maier W., Marchini J., Mbarek H., McGrath P., McGuffin P., Medland S., Mehta D., Middeldorp C., Mihailov E., Milaneschi Y., Milani L., Mill J., Mondimore F., Montgomery G., Mostafavi S., Mullins N., Nauck M., Ng B., Nivard M., Nyholt D., O'Reilly P., Oskarsson H., Owen M., Painter J., Pedersen C., Pedersen M., Peterson R., Pettersson E., Peyrot W., Pistis G., Posthuma D., Purcell S., Quiroz J., Qvist P., Rice J., Riley B., Rivera M., Mirza S., Saxena R., Schoevers R., Schulte E., Shen L., Shi J., Shyn S., Sigurdsson E., Sinnamon G., Smit J., Smith D., Stefánsson H., Steinberg S., Stockmeier C., Streit F., Strohmaier J., Tansey K., Teismann H., Teumer A., Thompson W., Thomson P., Thorgeirsson T., Tian C., Traylor M., Treutlein J., Trubetskoy V., Uitterlinden A., Umbricht D., Auwera S., Hemert A., Viktorin A., Visscher P., Wang Y., Webb B., Weinsheimer S., Wellmann J., Willemsen G., Witt S., Wu Y., Xi H., Yang J., Zhang F., Arolt V., Baune B., Berger K., Boomsma D., Cichon S., Dannlowski U., Geus E., DePaulo J., Domenici E., Domschke K., Esko T., Grabe H., Hamilton S., Hayward C., Heath A., Hinds D., Kendler K., Kloiber S., Lewis G., Li Q., Lucae S., Madden P., Magnusson P., Martin N., McIntosh A., Metspalu A., Mors O., Mortensen P., Müller-Myhsok B., Nordentoft M., Nöthen M., O'Donovan M., Paciga S., Pedersen N., Penninx B., Perlis R., Porteous D., Potash J., Preisig M., Rietschel M., Schaefer C., Schulze T., Smoller J., Stefánsson K., Tiemeier H., Uher R., Völzke H., Weissman M., Werge T., Winslow A., Lewis C., Levinson D., Breen G., Børglum A., and Sullivan P., 2017, Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression, Nature Genetics, 50: 668-681. Westrhenen R., Aitchison K., Ingelman-Sundberg M., and Jukic M., 2020, Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going?, Frontiers in Psychiatry, 11: 94. https://doi.org/10.3389/fpsyt.2020.00094 Zhou J.Y., 2024, The Application of genomics in personalized cancer therapy, Cancer Genetics and Epigenetics, 12(1): 66-74. https://doi.org/10.5376/cge.2024.12.0009
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==